Comprehensive proteomic analysis offers a powerful means of understanding cancer biology and treatment outcomes. However, conventional approaches often lack the throughput, scalability, coverage, and data interoperability required for large-scale or comparative studies. Advances in high-throughput quantitative proteomics now allow scientists to precisely, rapidly, and economically analyze thousands of samples.

In this webinar Lloyd Bod, PhD ( Harvard Medical School, Massachusetts General Hospital, Broad Institute) and Nathaniel Robichaud, PhD, (Nomic Bio) will discuss how large-scale profiling of the circulating proteome across multiple cancer types reveals unique tumor-specific protein signatures and provides new insights into treatment response.

Topics to be covered:

• Exploring biomarker discovery opportunities enabled by new proteomics tools
• Highlighting the unique proteomic features of multiple tumor types, including pancreatic, colorectal, melanoma, and Merkel cell carcinoma
• Characterizing immunotherapy-specific changes in the circulating proteome
• Identifying proteomic markers associated with therapeutic response

‍